Castle Biosciences Inc
NASDAQ:CSTL
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
17.4
34.67
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CSTL stock under the Base Case scenario is 32.02 USD. Compared to the current market price of 31.79 USD, Castle Biosciences Inc is Undervalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Castle Biosciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CSTL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Castle Biosciences Inc
Balance Sheet Decomposition
Castle Biosciences Inc
Current Assets | 344.8m |
Cash & Short-Term Investments | 279.8m |
Receivables | 50.3m |
Other Current Assets | 14.7m |
Non-Current Assets | 169.8m |
PP&E | 56.3m |
Intangibles | 110.6m |
Other Non-Current Assets | 2.9m |
Current Liabilities | 44.3m |
Accounts Payable | 6.8m |
Accrued Liabilities | 34.5m |
Other Current Liabilities | 3m |
Non-Current Liabilities | 29.2m |
Long-Term Debt | 10.3m |
Other Non-Current Liabilities | 18.9m |
Earnings Waterfall
Castle Biosciences Inc
Revenue
|
311.9m
USD
|
Cost of Revenue
|
-56.4m
USD
|
Gross Profit
|
255.4m
USD
|
Operating Expenses
|
-256.5m
USD
|
Operating Income
|
-1m
USD
|
Other Expenses
|
7.1m
USD
|
Net Income
|
6.1m
USD
|
Free Cash Flow Analysis
Castle Biosciences Inc
USD | |
Free Cash Flow | USD |
CSTL Profitability Score
Profitability Due Diligence
Castle Biosciences Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Castle Biosciences Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
CSTL Solvency Score
Solvency Due Diligence
Castle Biosciences Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Castle Biosciences Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CSTL Price Targets Summary
Castle Biosciences Inc
According to Wall Street analysts, the average 1-year price target for CSTL is 36.83 USD with a low forecast of 28.28 USD and a high forecast of 47.25 USD.
Dividends
Current shareholder yield for CSTL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
Contact
IPO
Employees
Officers
The intrinsic value of one CSTL stock under the Base Case scenario is 32.02 USD.
Compared to the current market price of 31.79 USD, Castle Biosciences Inc is Undervalued by 1%.